Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis by Windecker, Stephan et al.
Revascularisation versusmedical treatment in patients
with stable coronary artery disease: network
meta-analysis
OPEN ACCESS
StephanWindecker, Stefan Stortecky, Giulio G Stefanini, Bruno R daCosta, AnneWilhelmina Rutjes,
Marcello Di Nisio, Maria G Siletta, Ausilia Maione, Fernando Alfonso, Peter M Clemmensen,
Jean-Philippe Collet, Jochen Cremer, Volkmar Falk, Gerasimos Filippatos, Christian Hamm, Stuart
Head, Arie Pieter Kappetein, Adnan Kastrati, Juhani Knuuti, Ulf Landmesser, Günther Laufer,
Franz-Joseph Neumann, Dimitri Richter, Patrick Schauerte, Miguel Sousa Uva, David P Taggart,
Lucia Torracca, Marco Valgimigli, William Wijns, Adam Witkowski, Philippe Kolh, Peter Juni
Abstract
Objective To investigate whether revascularisation improves prognosis
compared with medical treatment among patients with stable coronary
artery disease.
Design Bayesian network meta-analyses to combine direct within trial
comparisons between treatments with indirect evidence from other trials
while maintaining randomisation.
Eligibility criteria for selecting studies A strategy of initial medical
treatment compared with revascularisation by coronary artery bypass
grafting or Food and Drug Administration approved techniques for
percutaneous revascularization: balloon angioplasty, bare metal stent,
early generation paclitaxel eluting stent, sirolimus eluting stent, and
zotarolimus eluting (Endeavor) stent, and new generation everolimus
eluting stent, and zotarolimus eluting (Resolute) stent among patients
with stable coronary artery disease.
Data sources Medline and Embase from 1980 to 2013 for randomised
trials comparing medical treatment with revascularisation.
Main outcome measure All cause mortality.
Results 100 trials in 93 553 patients with 262 090 patient years of
follow-up were included. Coronary artery bypass grafting was associated
with a survival benefit (rate ratio 0.80, 95% credibility interval 0.70 to
0.91) compared with medical treatment. New generation drug eluting
stents (everolimus: 0.75, 0.59 to 0.96; zotarolimus (Resolute): 0.65, 0.42
to 1.00) but not balloon angioplasty (0.85, 0.68 to 1.04), bare metal
stents (0.92, 0.79 to 1.05), or early generation drug eluting stents
(paclitaxel: 0.92, 0.75 to 1.12; sirolimus: 0.91, 0.75 to 1.10; zotarolimus
(Endeavor): 0.88, 0.69 to 1.10) were associated with improved survival
compared with medical treatment. Coronary artery bypass grafting
reduced the risk of myocardial infarction compared with medical treatment
(0.79, 0.63 to 0.99), and everolimus eluting stents showed a trend
towards a reduced risk of myocardial infarction (0.75, 0.55 to 1.01). The
risk of subsequent revascularisation was noticeably reduced by coronary
artery bypass grafting (0.16, 0.13 to 0.20) followed by new generation
drug eluting stents (zotarolimus (Resolute): 0.26, 0.17 to 0.40;
everolimus: 0.27, 0.21 to 0.35), early generation drug eluting stents
(zotarolimus (Endeavor): 0.37, 0.28 to 0.50; sirolimus: 0.29, 0.24 to 0.36;
paclitaxel: 0.44, 0.35 to 0.54), and bare metal stents (0.69, 0.59 to 0.81)
compared with medical treatment.
Conclusion Among patients with stable coronary artery disease,
coronary artery bypass grafting reduces the risk of death, myocardial
infarction, and subsequent revascularisation compared with medical
treatment. All stent based coronary revascularisation technologies reduce
the need for revascularisation to a variable degree. Our results provide
evidence for improved survival with new generation drug eluting stents
but no other percutaneous revascularisation technology compared with
medical treatment.
Introduction
While it is generally accepted that coronary revascularisation
reduces the risk of death and myocardial infarction compared
with initial medical treatment among patients with acute
coronary syndromes,1 2 the prognostic benefit is less well
established among patients with stable coronary artery disease.3 4
Compared with medical treatment, coronary artery bypass
grafting has been shown to convey a survival advantage5;
conversely, the benefit of percutaneous coronary interventions
remains debatable.6-8 None of the individual trials comparing
medical treatment with percutaneous coronary intervention have
shown a survival advantage, and meta-analyses revealed
conflicting results, with some reporting no difference9 10 and
others suggesting a modest benefit.10-12 Notwithstanding, none
of the randomised trials has been adequately powered to deal
with survival, whereas treatment effects were reduced owing
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to crossover to revascularisation in a sizable proportion of
patients and exclusion of high risk patients based on
angiographically defined extent of coronary artery disease.13 14
Moreover, revascularisation techniques havematured over time.
Nowadays, coronary artery bypass grafting systematically
employs the internal mammary artery with proved long term
patency and survival benefit.15 16 Similarly, percutaneous
coronary intervention has evolved with important historical
transitions from the era of balloon angioplasty,17 over bare metal
stents,18-20 to early generation, Food and Drug Administration
approved drug eluting stents,21-24 followedmore recently by new
generation drug eluting stents.25-27
A large number of trials compared the different revascularisation
strategies, including coronary artery bypass grafting,28 29 balloon
angioplasty,30 31 and percutaneous coronary intervention with
bare metal stents13 or with various FDA approved drug eluting
stents against medical treatment,32 as well as different
revascularisation strategies head to head.26 33 34
Network meta-analysis allows a unified analysis of the entire
set of available trials by combining all direct within trial
comparisons with indirect between trial comparisons of
interventions constructed from trials that have one intervention
in common, while fully respecting randomisation.35 36 We
established a collaborative group of investigators consisting of
cardiovascular surgeons and interventional and non-invasive
cardiologists with expertise in the specialty of revascularisation,
and conducted a network meta-analysis of all available trials to
provide novel evidence in view of several recently reported
trials and major technological advances in revascularisation and
medical treatment.
Methods
Literature search and study selection
We searched Medline and Embase from 1980 to June 2013,
using the methodological filters proposed by the Cochrane
Collaboration to search for randomised clinical trials (see
supplementary appendix). In addition, we hand searched
reference lists of relevant reviews. Two investigators (GS, SS)
assessed reports for eligibility. To be included in the analysis,
studies had to be randomised controlled trials in patients with
symptomatic or asymptomatic stable coronary artery disease or
in unselected patient populations. Trials had to have a clinical
follow-up duration of at least six months and were required to
randomise at least 100 patients per trial arm. Patients had to be
randomised to medical treatment, coronary artery bypass
grafting, or percutaneous coronary intervention using balloon
angioplasty, bare metal stents, early generation stent systems
(paclitaxel eluting Taxus stent (Boston Scientific, Natick, MA),
sirolimus eluting Cypher stent (Cordis, Miami Lakes, FL),
zotarolimus eluting Endeavor stent (Medtronic Cardiovascular,
Santa Rosa, CA)) or new generation stent systems (zotarolimus
eluting Resolute stent (Medtronic Cardiovascular, Santa Rosa,
CA) and everolimus eluting Xience/Promus stent (Abbott
Vascular, Santa Clara, CA and Boston Scientific, Natick, MA))
approved by the FDA.We excluded trials in patients with acute
myocardial infarction (ST segment elevation myocardial
infarction or non-ST segment elevation myocardial infarction)
and symptom onset less than 72 hours, trial arms with polymer
or carbon coated bare metal stents, and trial arms with non-FDA
approved drug eluting stents.
Data collection and outcomes
Four investigators (MdN, MGS, AM, or AR) independently
extracted data, with disagreement resolved in consultation with
another investigator (SS, GS, or PJ). We prespecified all cause
mortality as the primary outcome, and myocardial infarction, a
composite of death or myocardial infarction, and subsequent
revascularisation as secondary outcomes. Subsequent
revascularisation was defined as percutaneous or surgical
revascularisation of the target lesion. If rates of target lesion
revascularisation were not reported, we used rates of target
vessel revascularisation or any revascularisation as a proxy
measure. We extracted outcome data at the follow-up closest
to five years.We assessed three key domains of internal validity,
concealment of allocation, blind adjudication of outcomes, and
the inclusion of all randomised participants in the analysis
according to the intention to treat principle (see supplementary
appendix).
Statistical analysis
The network meta-analysis was based on a bayesian random
effects Poisson regression model, which preserves randomised
treatment comparisons within trials.36-39Themodel uses numbers
of patients experiencing an event and accumulated patient years
to estimate rate ratios. The specification of nodes in the network
were based on the randomised intervention or in case of strategy
trials, such as COURAGE13 or FAME-2,32 on the intervention
received by the majority of patients in a trial arm. Analyses
were performed using Markov-Chain Monte-Carlo methods.
The prior distribution for treatment effects was minimally
informative: a normal distribution with a mean of 1 and a 95%
reference range from 0.01 to 100 on a rate ratio scale. The prior
for the between trial variance τ2, which we assumed to be equal
across comparisons, was based on empirical evidence derived
from semi-objective outcomes of head to head comparisons40:
a log normal distribution with a geometric mean of τ2 of 0.04
and a 95% reference range from 0.001 to 1.58. Rate ratios were
estimated from the median and corresponding 95% credibility
intervals from the 2.5th and 97.5th centiles of the posterior
distribution. We performed primary analyses in all trials;
secondary analyses were restricted to contemporary trials with
start of patient enrolment in 1999 or later, which corresponds
to the start of patient enrolment in COURAGE.13We performed
sensitivity analyses restricted to trials with adequate concealment
of allocation; restricted to trials with blinded adjudication of
events; restricted to trials with analysis according to the intention
to treat principle; excluding trials that assigned patients to
revascularisationwith coronary artery bypass grafting; excluding
“all comer” trials in unselected populations and trials in patients
post-myocardial infarction, defined as patients with a history
of myocardial infarction more than 72 hours to three months
before randomisation; excluding trials with less than two years’
follow-up; excluding trials with more than 10% of patients lost
to follow-up; and performing bayesian random effects
meta-analyses for all available direct randomised comparisons.
In additional sensitivity analyses, we used different priors for
τ2 and used frequentist network meta-analyses to calculate rate
ratios and risk ratios without the use of priors. To examine the
data for small study effects, we constructed comparison adjusted
funnel plots (see supplementary appendix). Convergence was
deemed to be achieved if plots of the Gelman-Rubin statistics41
indicated that widths of pooled runs and individual runs
stabilised around the same value and their ratio was around 1.
Given these criteria, we based our calculations on the 20 001
to 50 000 iterations, discarding the first 20 000 iterations as
burn-in. We examined the inconsistency of the network by
calculating loop specific inconsistency factors, and an omnibus
test to derive an overall P value for inconsistency, which took
into account multiple testing of potentially correlated
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inconsistency factors.42 Inconsistent loops were examined
individually for sources of inconsistency. Statistical
heterogeneity between trials was estimated from the median
between trial variance τ2 observed in the posterior distribution,
and goodness of fit of the model was assessed using residual
deviances.38 Analyses were done in Stata 12.1 and WinBUGS
1.4.
Results
Characteristics of trials and patients
Supplemental figure 1 presents the flow chart of the study and
summarises the process of identifying trials. We screened the
titles and abstracts of 14 888 potentially eligible reports,
examined the full text of 620 articles, and identified 399 articles
on 100 trials that met our inclusion criteria. Table 1⇓ presents
the characteristics of the included trials. The characteristics of
the patients and their diseases in the eligible studies are
summarised in the supplementary appendix and the
characteristics of treatment arms are summarised in table 2⇓.
Figure 1⇓ shows the network of evidence. The bare metal stent
was investigated most (50 trials) and compared with seven
different interventions, whereas the zotarolimus eluting
(Resolute) stent was evaluated least (four trials) and compared
with three different interventions. For the primary endpoint all
cause mortality, the sirolimus eluting stent and bare metal stent
had the largest number of patient years (45 879 and 45 467,
respectively) and the zotarolimus eluting (Resolute) stent the
lowest number (3384 patient years). Overall, 93 553 patients
were randomised and we included follow-up of 260 090 patient
years in the analysis of the primary endpoint.
In general, trials were considered to be of high methodological
quality. Appropriate methods of allocation concealment were
described for 71 trials (71%). Fifty six trials (56%) reported
blind adjudication of clinical outcomes, and for 69 trials (69%)
we were able to include all randomised patients into the analysis
according to the intention to treat principle. Supplementary table
2 presents the raw numbers of events separately for each trial
at the follow-up closest to five years. Supplementary table 3
provides a breakdown of the number of patients, events, and
accumulated patient years by intervention. Figure 2⇓ provides
the cumulative number of patients randomly assigned to different
types of intervention over time. Figure 3⇓ presents the rate ratios
of clinical outcomes of revascularisation compared with medical
treatment.
All cause mortality
Ninety five trials including 93 553 randomised patients and
5346 accumulated events contributed to the analysis of all cause
mortality. Compared with a strategy of initial medical treatment,
revascularisation using coronary artery bypass grafting reduced
all cause mortality by 20% (rate ratio 0.80, 95% credibility
interval 0.70 to 0.91). Percutaneous coronary intervention with
new generation drug eluting stents, but no other percutaneous
coronary intervention technology, was also associated with
reducedmortality compared withmedical treatment (everolimus
eluting: 0.75, 0.59 to 0.96; zotarolimus eluting (Resolute): 0.65,
0.42 to 1.00). The estimated rate ratios for mortality were below
1, but inconclusive for revascularisationwith balloon angioplasty
(0.85, 0.68 to 1.04), bare metal stents (0.92, 0.79 to 1.05), and
early generation drug eluting stents (paclitaxel eluting: 0.92,
0.75 to 1.12; sirolimus eluting: 0.91, 0.75 to 1.10; zotarolimus
eluting (Endeavor): 0.88, 0.69 to 1.10).
Myocardial infarction
Ninety two trials including 90 472 randomised patients
contributed to the endpoint analysis of myocardial infarction
(see supplementary tables 2 and 3). Overall, 5796 events were
reported during 243 031 patient years and contributed to the
analysis of myocardial infarction. Revascularisation using
coronary artery bypass grafting compared with medical
treatment reducedmyocardial infarction during the observational
period by 21% (0.79, 0.63 to 0.99). All percutaneous coronary
interventions, except bare metal stent (1.04, 0.84 to 1.27) and
paclitaxel eluting stent (1.18, 0.88 to 1.54), showed evidence
for a relevant but inconclusive reduction of myocardial
infarction, with point estimates below 1 for balloon angioplasty
(0.88, 0.70 to 1.11), sirolimus eluting stent (0.94, 0.71 to 1.22),
zotarolimus eluting (Endeavor) stent (0.80, 0.56 to 1.10),
zotarolimus eluting (Resolute) stent (0.82, 0.52 to 1.26), and
everolimus eluting stent (0.75, 0.55 to 1.01).
Composite of death or myocardial infarction
Eighty eight trials including 89 373 randomised patients and
8936 accumulated events during 233 030 patient years
contributed to the analysis of the composite endpoint death or
myocardial infarction (see supplementary tables 2 and 3).
Compared with medical treatment, revascularisation using
coronary artery bypass grafting, balloon angioplasty, and
everolimus eluting stent was associated with a significant
reduction of death or myocardial infarction by 19% (0.81, 0.70
to 0.94), 17% (0.83, 0.70 to 0.97), and 22% (0.78, 0.63 to 0.96),
respectively. No other percutaneous revascularisation technology
was effective in showing a significant reduction in death or
myocardial infarction, although point estimates were in favour
of revascularisation with sirolimus eluting stent (0.96, 0.79 to
1.13), zotarolimus eluting (Endeavor) stent (0.85, 0.67 to 1.05),
and zotarolimus eluting (Resolute) stent (0.81, 0.59 to 1.10).
Subsequent revascularisation
Ninety four trials in 90 282 patients contributed to the analysis
of subsequent revascularisation (see supplementary tables 2 and
3). Subsequent coronary revascularisation events were reported
in 11 619 patients during the follow-up duration of 234 693
patient years and contributed to the analysis of subsequent
revascularisation.
Compared with medical treatment, revascularisation with
coronary artery bypass grafting was effective in reducing
subsequent revascularisation by 84% (0.16, 0.13 to 0.20).
Revascularisation using coronary stents was associated with a
reduction in subsequent revascularisation for bare metal stent
(0.44, 0.59 to 0.82), paclitaxel eluting stent (0.44, 0.35 to 0.55),
sirolimus eluting stent (0.29, 0.24 to 0.36), zotarolimus eluting
(Endeavor) stent (0.38, 0.29 to 0.51), zotarolimus eluting
(Resolute) stent (0.26, 0.17 to 0.40), and everolimus eluting
stent (0.27, 0.21 to 0.35). Revascularisation with balloon
angioplasty showed similar risks of subsequent revascularisation
compared with medical treatment (0.97, 0.82 to 1.16).
Restriction to contemporary trials
Figure 4⇓ presents results from analyses restricted to 88
contemporary trials which were initiated in 1999 or later, in 85
720 patients. Compared with the main analysis, point estimates
of the rate ratio of all cause mortality moved closer to the null
effect line, and 95% credibility intervals became wider, with a
rate ratio of 0.85 for coronary artery bypass grafting (0.72 to
1.00), 0.82 for everolimus eluting stent (0.65 to 1.03), and 0.71
for zotarolimus eluting (Resolute) stent (0.46 to 1.11) compared
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with medical treatment. For myocardial infarction, the rate ratio
for coronary artery bypass grafting moved towards more benefit
(0.48, 0.37 to 0.64), and results became statistically more robust
for the everolimus eluting stent (0.73, 0.57 to 0.95). For the
composite of death or myocardial infarction and for
revascularisation, results were similar to the main analysis.
Additional analyses
Supplementary table 4 presents rankings of different
interventions compared with medical treatment in analyses of
all trials, and supplementary table 5 shows the rankings in
analyses of contemporaneous trials only. Table 3⇓ presents
results of sensitivity analyses. Point estimates of treatment
effects were similar to those derived for the main analysis for
all outcomes and interventions, and overlapping 95% credibility
intervals indicated that estimates from all sensitivity analyses,
including conventional random effects meta-analyses of pairwise
comparisons, were compatible with the main analysis.
Supplementary table 6 presents estimated rate ratios of all
possible comparisons from conventional meta-analysis of direct
randomised comparisons and network meta-analysis; estimates
from network and conventional meta-analysis, where available,
were compatible. Supplementary figure 2 presents comparison
adjusted funnel plots, without evidence of asymmetry.
Supplementary table 7 presents results based on the use of
different priors in bayesian analyses and frequentist network
meta-analyses using rate ratios or risk ratios. Estimates remained
robust to the use of different assumptions.
Model fit, heterogeneity between trials, and
consistency of the network
Model fit was adequate (see supplementary table 8) and
heterogeneity between trials low for all outcomes (range of τ2
across outcomes 0.003 to 0.047; supplementary table 9). There
was no evidence of inconsistency for the primary outcome of
overall mortality (P for inconsistency=0.98), and 95% credibility
intervals of all loop specific inconsistency factors overlapped
the null (see supplementary figure 3). For the composite of death
or myocardial infarction, 95% credibility intervals of two
correlated loops, both involving coronary artery bypass grafting,
did not cross the null, but the overall test for inconsistency was
negative (P for inconsistency=0.27). For myocardial infarction,
95% credibility intervals of three loops did not overlap the null,
two involving coronary artery bypass grafting, and the overall
test for inconsistency was positive (P for inconsistency=0.015).
For revascularisation, 95% credibility intervals of four loops
did not overlap the null, three involving coronary artery bypass
grafting, again with a positive overall test for inconsistency (P
for inconsistency <0.001). After restriction to contemporary
trials, model fit remained adequate (see supplementary table 8)
and heterogeneity between trials low for all outcomes (see
supplementary table 9). Signals of inconsistency completely
disappeared for myocardial infarction but persisted for
revascularisation (see supplementary figure 4). Likely sources
of inconsistency in the analysis of myocardial infarction were
the 12 coronary artery bypass grafting trials initiated before
1999, which yielded a pooled rate ratio of 0.99 compared with
medical treatment, balloon angioplasty or bare metal stent (95%
credibility interval 0.81 to 1.20, τ2=0.050) compared with the
six contemporary coronary artery bypass grafting trials, which
yielded a pooled ratio of 0.49 compared with medical treatment
or early generation drug eluting stents (0.40 to 0.60, τ2=0.000).
The overall test for inconsistency became negative after
exclusion of five coronary artery bypass grafting trials, which
showed increases in the risk of myocardial infarction associated
with coronary artery bypass grafting between 34% and 133%
(see supplementary figure 5). Likely sources of inconsistency
in the analysis of subsequent revascularisation were the
FREEDOM and CARDia trials, which showed that the
probability of subsequent revascularisation was reduced
approximately three and six times with coronary artery bypass
grafting compared with early generation drug eluting stents in
people with diabetes, and the RESOLUTE China trial, which
showed a fourfold reduction in subsequent revascularisations
with the zotarolimus eluting (Resolute) stent compared with
early generation drug eluting stents. The overall test for
inconsistency remained positive after exclusion of these trials
in the overall analysis but became negative in the analysis of
contemporary trials (see supplementary figure 5), which showed
only one inconsistent loop. Supplementary table 10 shows that
estimates after exclusion of likely sources of inconsistency were
similar to estimates from main analyses.
Discussion
The salient findings of our network meta-analysis of 100 trials
in 93 553 patients with stable coronary artery disease comparing
revascularisation by coronary artery bypass grafting or various
FDA approved percutaneous revascularisation technologies
against medical treatment as initial strategy can be summarised
as follows: coronary artery bypass grafting is associated with a
statistically robust survival benefit compared with initial medical
treatment; new generation drug eluting stents, but not balloon
angioplasty, bare metal stents, or early generation drug eluting
stents, are associated with improved survival compared with
initial medical treatment; coronary artery bypass grafting reduces
the risk of myocardial infarction compared with initial medical
treatment; and the risk of subsequent revascularisation is
noticeably reduced by coronary artery bypass grafting followed
by new generation drug eluting stents, early generation drug
eluting stents, and bare metal stents.
In secondary analyses of 88 contemporary trials in 85 720
patients, which were initiated in 1999 or later, we found these
results confirmed, with the exception of myocardial infarction,
which showed considerablymore pronounced treatment benefits
of coronary artery bypass grafting and statistically more robust
benefits of everolimus eluting stents. Since signals of
inconsistency observed in the primary analysis of myocardial
infarction completely disappeared in this secondary analysis,
we deem the 52% reduction in the risk of myocardial infarction
observed in the secondary analysis a more reliable estimate of
the effects of contemporary revascularisation with coronary
artery bypass grafting on myocardial infarction than the 21%
reduction found in the primary analysis.
The most important finding of the present analysis is that several
revascularisation techniques—notably, coronary artery bypass
grafting and new generation drug eluting stents—are associated
with improved survival compared with an initial strategy of
medical treatment alone among patients with stable coronary
artery disease. The survival benefit over medical treatment is
well established for coronary artery bypass grafting5 but novel
for percutaneous coronary intervention with new generation
drug eluting stents. Our study corroborates previous reports on
coronary artery bypass grafting and extends the observed benefit
to contemporaneous study populations included in more recent
trials with more effective medical regimens,28 33 increased use
of arterial bypass grafts, and improved perioperative
management, providing a statistically more robust estimate of
the associated survival benefit.
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Themechanism underlying the survival benefit of both coronary
artery bypass grafting and new generation drug eluting stents
compared with initial medical treatment seems to be related in
part to a lower risk of myocardial infarction. The lower risk of
myocardial infarction with coronary artery bypass grafting
compared with medical treatment is explained by the protective
effect of patent grafts against proximal vessel occlusions.43
Similarly, new generation drug eluting stents—specifically
everolimus eluting stents—were associated with a trend towards
a lower risk of myocardial infarction. Compared with previously
used percutaneous revascularisation techniques, new generation
drug eluting stents have been consistently shown to afford a
reduction in the risk of myocardial infarction and stent
thrombosis.44 A recent network meta-analysis reported a
profound reduction of stent thrombosis with everolimus eluting
stents compared not only with other drug eluting stents but also
with bare metal stents45—a finding that is supported by
experimental evidence of antithrombotic properties of
everolimus eluting stents.46 Moreover, direct comparisons of
everolimus eluting stents with early generation paclitaxel eluting
stents and to a lesser degree with sirolimus eluting stents have
shown a lower risk of myocardial infarction with everolimus
eluting stents.25 47 It is therefore likely that the improved safety
profile of new generation drug eluting stents in terms of
myocardial infarction and stent thrombosis translates into
improved survival compared with initial medical treatment by
providing effective revascularisation without the associated risk
of stent related adverse effects.
Our study provides a nuanced interpretation of the benefit of
percutaneous coronary intervention techniques over initial
medical treatment in terms of survival and the risk of myocardial
infarction, which seems to be directly related to the device type
used for revascularisation. While older technologies conferred
no apparent benefit comparedwithmedical treatment, the advent
of new generation drug eluting stents apparently resulted in a
survival benefit. A previous network meta-analysis comparing
percutaneous coronary intervention with medical treatment was
limited to the inclusion of early generation paclitaxel eluting
stents and sirolimus eluting stents and observed no benefit in
relation tomedical treatment in terms of survival andmyocardial
infarction.6 The present study importantly extends this analysis
by the addition of new generation FDA approved drug eluting
stents as well as comparisons with coronary artery bypass
grafting. Against this background, the missing survival benefit
of percutaneous coronary intervention compared with medical
treatment in the COURAGE trial has to be interpreted in view
of the device used—namely, bare metal stents.13 More recent
studies comparing initial medical treatment with new generation
drug eluting stents, such as ISCHEMIA (ClinicalTrials.gov
NCT01471522), have the potential to disclose a benefit in
ischaemic endpoints in favour of drug eluting stents. Enrolment
into FAME II was interrupted early after interim analyses
disclosed an excess of primary endpoint events amongmedically
treated patients largely driven by urgent revascularisation
procedures, which in about half of cases had evidence of
ongoing ischaemia on electrocadiography or myocardial
infarction.32
Coronary artery bypass grafting resulted in the strongest
reduction in the need for revascularisation compared with
medical treatment (>80%), which was superior to any
percutaneous coronary intervention technology, including new
generation drug eluting stents. Among percutaneous
revascularisation technologies, continuous progress in the need
of revascularisation compared with medical treatment was
observed over time, which was reduced by approximately 30%
with bare metal stents, 60% with early generation paclitaxel
eluting stents and zotarolimus eluting (Endeavor) stent, and
more than 70% with early generation sirolimus eluting stents
and new generation everolimus eluting stents and the
zotarolimus eluting (Resolute) stent compared with medical
treatment. Of note, the potent reduction in revascularisation
with new generation drug eluting stents was not associated with
any safety concerns. In fact, new generation everolimus eluting
stents combined one of the best efficacy profiles among drug
eluting stents with improved survival and a trend towards a
lower risk of myocardial infarction compared with medical
treatment alone. Notwithstanding, even new generation drug
eluting stents remained less effective than coronary artery bypass
grafting for risk of subsequent revascularisation. This is
important as percutaneous coronary intervention irrespective
of device type results in less complete revascularisation.
Therefore the selection of revascularisation modality remains
important, particularly among patients with advanced coronary
artery disease.
Limitations of this study
The present analysis has to be interpreted in view of several
limitations. Firstly, any revascularisation technique, coronary
artery bypass grafting, or percutaneous coronary intervention
is associated with a risk of periprocedural myocardial infarction,
which is typically diagnosed by increases in biomarkers despite
the absence of symptoms or electrocardiographic changes, and
the prognostic importance of periprocedural myocardial
infarction remains disputed. In our analysis we were, however,
unable to distinguish between periprocedural and spontaneous
myocardial infarction. Several studies indicate that preprocedural
rather than post-procedural increases in biomarkers are
associated with impaired prognosis48 and that only large
periprocedural myocardial infarctions are associated with poor
outcome.49 This is of importance, as a recent meta-analysis
comparing percutaneous coronary intervention with initial
medical treatment reported a lower risk of spontaneous
myocardial infarction with percutaneous coronary intervention,
which was offset by an increased risk of periprocedural
myocardial infarction.10 A distinction of different types of
myocardial infarction could therefore have improved our
understanding of the mechanisms behind the observed survival
benefit with coronary artery bypass grafting and new generation
drug eluting stents. Since periprocedural myocardial infarctions
preferentially occur among patients undergoing
revascularisation, a restriction of the analysis to spontaneous
myocardial infarction would have resulted in amore pronounced
reduction in myocardial infarction with revascularisation.
Secondly, our analysis was based on the intention to treat
principle, with randomised patients analysed in the group to
which they were originally allocated irrespective of subsequent
crossovers to revascularisation among patients allocated to
medical treatment. This will have resulted in an underestimation
of the true benefits of revascularisation.
Thirdly, some will argue that the inclusion of stable patients
with recent myocardial infarction and trials with all comer
populations including patients with acute coronary syndromes
may have biased results in favour of revascularisation. However,
a sensitivity analysis excluding trials in these patient populations
yielded much the same results as the primary analysis (table 3).
Fourthly, the trials included in the network meta-analysis were
performed over a period of several decades, during which
clinical practice and optimal medical treatment for patients with
coronary artery disease have evolved. Although we cannot
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exclude that changes in medical treatment over time have
affected the results of this analysis, we deem this unlikely. Our
analysis preserves randomised treatment comparisons within
trials, statistical heterogeneity was low for all outcomes, our
model with its assumptions fitted the trial data adequately, and
there was no evidence of inconsistency for the primary outcome
of all-cause mortality. Sources of residual inconsistency for
myocardial infarction and subsequent revascularisation were
explained by reasons other than concomitant medical treatment.
Fifthly, the results of the current analysis are derived from
patient populations enrolled into randomised trials and may not
necessarily apply to all patients encountered in routine clinical
practice. Moreover, diagnostic angiography preceded
randomisation inmost strategy trials comparing revascularisation
with medical treatment, which is likely to have resulted in the
exclusion of higher risk patients.
Sixthly, in the absence of individual patient data we were forced
to assume in the analysis that event rates in each trial arm were
constant over time, when in reality event rates are likely to be
higher during the first 30 days after randomisation.35 A
sensitivity analysis of risk ratios, which does not make this
assumption, showed nearly identical results, however. In
addition, we assumed that the between trial variance τ2 is equal
across comparisons, as is commonly done in network
meta-analysis. This may be criticised, but was inevitable, since
it allowed us to borrow strength for estimating heterogeneity
across different comparisons, when some comparisons were
based on a few or even a single trial only.50
Seventhly, the absence of individual patient data means that the
present analysis provides average risk estimates and does not
allow the evaluation of specific subgroups. It remains to be
determinedwhether the observed treatment effects are consistent
among specific high risk patient populations, such as patients
with multivessel disease, diabetes, or left ventricular
dysfunction, and it cannot be excluded that the advantages of
coronary artery bypass grafting are more pronounced in certain
subgroups of patients than observed on average in our analysis.
Finally, we were unable to distinguish between the angiographic
extent of severity of coronary artery disease and functional
extent of ischaemic myocardium from the data extracted for
this analysis. Recent changes in clinical practice guidelines,
however, highlight the importance of functional lesion severity
before revascularisation. An individual patient data network
meta-analysis, even though demanding, would enable the
limitations discussed here to be addressed.
Using network meta-analysis, we included data from 100 trials
in 93 553 patients. Our model fully preserved randomisation
within each trial but integrated evidence from direct and indirect
comparisons to borrow strength from the entire network of
trials.35 Our approach resulted in a gain in statistical precision,
particularly for mortality and myocardial infarction that had
only been imprecisely estimated in previous analyses. Ourmodel
is based on relative treatment effects (log rate ratios), and
variations in patient characteristics andmedical co-interventions
between trials are accounted for in the analysis by preserving
randomised comparisons within each trial. Network
meta-analysis makes similar assumptions to standard
meta-analysis, but requires that these assumptions hold over the
entire set of trials of the network. Additional assumptions, which
are specific for network meta-analysis, are that the model fits
the data and that the network of trials is consistent, with no
relevant differences in estimates between direct and indirect
comparisons. In view of low statistical heterogeneity, a lack of
inconsistency, and excellent model fit, it is likely that these
assumptions were fully satisfied over the entire set of trials
covering a period of more than 30 years for the primary outcome
of all cause mortality. For myocardial infarction, the secondary
analysis restricted to contemporaneous trials is likely to be more
reliable than the primary analysis of all trials, since signals of
inconsistency initially found for myocardial infarction
completely disappeared in the restricted analysis. For the
outcome of subsequent revascularisation, we found evidence
of inconsistency in both primary and secondary analysis, even
though model fit was adequate and heterogeneity between trials
low. In view of the magnitude of observed average effects, this
does not, however, invalidate our conclusions that coronary
artery bypass grafting is associated with the largest benefits on
this outcome, followed by new generation drug eluting stents.
Conclusions
Among patients with stable coronary artery disease, coronary
artery bypass grafting reduces the risk of death, myocardial
infarction, and the need for revascularisation compared with
medical treatment. All stent based percutaneous coronary
interventions reduce the need for revascularisation to a variable
degree. Our results provide evidence for improved survival with
new generation drug eluting stents but no other percutaneous
coronary intervention compared with medical treatment.
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Tables
Table 1| Characteristics of randomised trials. Values are medians (ranges) unless stated otherwise
Total (n=100)Characteristics
510 (200-8709)No of patients randomised
62 (51-69)Average age (years)
24 (0-42)% women
55 (34-80)% with multivessel disease
59.5 (56-61.2)Left ventricular ejection fraction (%)
23 (16-31)% of patients with diabetes
2007 (1982-2013)Year of publication
Intervention arms (No of trials/No of randomised patients):
15 (7010)Medical treatment
22 (8920)Coronary artery bypass grafting
29 (7609)Percutaneous transluminal coronary angioplasty
50 (16 042)Bare metal stent
27 (11 541)Paclitaxel eluting stent
39 (19 781)Sirolimus eluting stent
8 (8937)Zotarolimus eluting (Endeavor) stent
4 (2285)Rotarolimus eluting (Resolute) stent
17 (13 272)Everolimus eluting stent
Methodological characteristics (No (%) of trials):
71 (71)Adequate allocation concealment
56 (56)Blind event adjudication
69 (69)Intention to treat analysis performed
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Table 2| Characteristics of treatment arms
No of events
Follow-up (patient
years)*Treatment
Subsequent
revascularisation
Death or myocardial
infarctionMyocardial infarctionAll cause mortality
170996754185730 628Medical treatment
556117055397038 709CABG
216470645129617 678PTCA
2873162894685245 467BMS
1203110466356727 592PES
14341752132190945 879SES
71968378844527 134E-ZES
144180130553384R-ZES
81774640339523 619EES
CABG=coronary artery bypass grafting; PTCA=percutaneous transluminal coronary angioplasty; BMS=bare metal stent; PES=paclitaxel eluting stent; SES=sirolimus
eluting stent; E-ZES=zotarolimus eluting (Endeavor) stent; R-ZES=zotarolimus eluting (Resolute) stent; EES=everolimus eluting stent.
*For the primary endpoint all cause death.
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Table 3| Sensitivity analyses
Conventional
meta-analysis*
Network meta-analysis
Outcomes by
interventions All trials
Trials with
≥24 months
of follow-up
Trials with
≤10% lost to
follow-up
Excluding all
comer and
post-MI trials
Excluding
CABG trials
Intention to
treat
analysis
Adjudication
blinded
Allocation
concealed
95 trials with
260 090 PY
54 trials with
230 503 PY
76 trials with
217 371 PY
77 trials with
174 343 PY
73 trials with
180 269 PY
66 trials with
206 937 PY
55 trials with
201 157 PY
67 trials with
195 142 PY
All causemortality:
0·77 (0.57 to
0.98)
0.80 (0.70 to
0.91)
0.79 (0.69 to
0.90)
0.75 (0.64 to
0.87)
0.81 (0.70 to
0.93)
—0.84 (0.73 to
0.95)
0.87 (0.73 to
1.04)
0.83 (0.69 to
0.99)
CABG v medical
treatment
0·66 (0.25 to
1.56)
0.85 (0.68 to
1.04)
0.81 (0.64 to
1.02)
0.82 (0.65 to
1.02)
0.85 (0.68 to
1.05)
0.85 (0.63 to
1.15)
0.91 (0.73 to
1.12)
0.88 (0.64 to
1.22)
0.92 (0.73 to
1.15)
PTCA v medical
treatment
0·99 (0.74 to
1.26)
0.92 (0.79 to
1.05)
0.94 (0.81 to
1.09)
0.91 (0.74 to
1.09)
0.92 (0.77 to
1.06)
0.95 (0.78 to
1.13)
0.94 (0.80 to
1.09)
0.98 (0.83 to
1.15)
0.96 (0.77 to
1.19)
BMS v medical
treatment
Early generation
DES:
—0.92 (0.75 to
1.12)
0.96 (0.78 to
1.18)
0.89 (0.70 to
1.10)
0.94 (0.74 to
1.18)
0.92 (0.69 to
1.20)
1.01 (0.80 to
1.26)
0.95 (0.75 to
1.20)
0.93 (0.72 to
1.19)
PES v medical
treatment
—0.91 (0.75 to
1.10)
0.94 (0.76 to
1.13)
0.91 (0.72 to
1.13)
1.00 (0.79 to
1.24)
0.91 (0.69 to
1.17)
0.95 (0.76 to
1.19)
0.94 (0.75 to
1.15)
0.87 (0.67 to
1.13)
SES v medical
treatment
—0.88 (0.69 to
1.10)
0.91 (0.71 to
1.15)
0.85 (0.65 to
1.09)
0.79 (0.57 to
1.11)
0.88 (0.65 to
1.16)
0.95 (0.73 to
1.25)
0.91 (0.70 to
1.15)
0.89 (0.67 to
1.18)
E-ZES v medical
treatment
New generation
DES:
—0.65 (0.42 to
1.00)
0.65 (0.38 to
1.11)
0.65 (0.41 to
1.02)
NA0.65 (0.42 to
1.02)
NA0.68 (0.43 to
1.07)
0.65 (0.41 to
1.03)
R-ZES v medical
treatment
0.33 (0.03 to
3.16)
0.75 (0.59 to
0.96)
0.81 (0.63 to
1.03)
0.74 (0.56 to
0.95)
0.63 (0.45 to
0.90)
0.75 (0.56 to
1.00)
0.83 (0.63 to
1.07)
0.79 (0.62 to
1.02)
0.76 (0.58 to
1.02)
EES v medical
treatment
92 trials with
243 031 PY
50 trials with
214 188 PY
74 trials with
203 166 PY
75 trials with
158 564 PY
75 trials with
182 347 PY
63 trials with
194 515 PY
55 trials with
194 710 PY
65 trials with
183 637 PY
Myocardial
infarction:
0.69 (0.23 to
1.89)
0.79 (0.63 to
0.99)
0.77 (0.58 to
1.01)
0.78 (0.59 to
1.01)
0.80 (0.63 to
1.03)
—0.80 (0.62 to
1.02)
0.69 (0.51 to
0.95)
0.77 (0.53 to
1.10)
CABG v medical
treatment
0.87 (0.34 to
2.30)
0.88 (0.70 to
1.11)
0.82 (0.59 to
1.13)
0.89 (0.68 to
1.15)
0.88 (0.68 to
1.12)
0.98 (0.79 to
1.22)
0.89 (0.69 to
1.15)
0.92 (0.67 to
1.26)
0.92 (0.67 to
1.27)
PTCA v medical
treatment
1.07 (0.63 to
1.50)
1.04 (0.84 to
1.27)
1.02 (0.77 to
1.32)
1.07 (0.81 to
1.38)
1.01 (0.80 to
1.25)
1.11 (0.94 to
1.32)
1.04 (0.83 to
1.30)
1.04 (0.81 to
1.29)
1.02 (0.73 to
1.38)
BMS v medical
treatment
Early generation
DES:
—1.18 (0.88 to
1.54)
1.20 (0.81 to
1.73)
1.21 (0.87 to
1.64)
1.28 (0.92 to
1.74)
1.05 (0.82 to
1.36)
1.33 (0.92 to
1.87)
1.04 (0.74 to
1.40)
1.14 (0.79 to
1.67)
PES v medical
treatment
—0.94 (0.71 to
1.22)
0.90 (0.62 to
1.27)
0.98 (0.70 to
1.32)
1.05 (0.77 to
1.40)
0.82 (0.64 to
1.06)
1.08 (0.76 to
1.49)
0.84 (0.61 to
1.12)
0.89 (0.61 to
1.28)
SES v medical
treatment
—0.80 (0.56 to
1.10)
0.75 (0.48 to
1.14)
0.84 (0.56 to
1.20)
0.76 (0.49 to
1.14)
0.76 (0.57 to
1.01)
0.99 (0.66 to
1·46)
0.73 (0.50 to
1.02)
0.80 (0.52 to
1.20)
E-ZES v medical
treatment
New generation
DES:
—0.82 (0.52 to
1.26)
0.79 (0.36 to
1.71)
0.85 (0.53 to
1.33)
NA0.73 (0.50 to
1.04)
NA0.75 (0.48 to
1.17)
0.78 (0.48 to
1.27)
R-ZES v medical
treatment
1.06 (0.51 to
2.19)
0.75 (0.55 to
1.01)
0.70 (0.46 to
1.06)
0.77 (0.54 to
1.07)
0.84 (0.57 to
1.22)
0.67 (0.51 to
0.89)
0.89 (0.60 to
1.27)
0.70 (0.50 to
0.96)
0.72 (0.49 to
1.07)
EES v medical
treatment
88 trials with
233 030 PY
49 trials with
204 959 PY
72 trials with
194 454 PY
71 trials with
148 563 PY
71 trials with
172 346 PY
61 trials with
190 173 PY
53 trials with
184 970 PY
63 trials with
174 559 PY
Death or
myocardial
infarction:
0.76 (0.37 to
1.48)
0.81 (0.70 to
0.94)
0.80 (0.68 to
0.95)
0.77 (0.65 to
0.90)
0.83 (0.71 to
0.98)
—0.82 (0.70 to
0.95)
0.81 (0.66 to
1.03)
0.79 (0.60 to
0.98)
CABG v medical
treatment
0.69 (0.25 to
1.86)
0.83 (0.70 to
0.97)
0.79 (0.64 to
0.97)
0.81 (0.68 to
0.98)
0.83 (0.69 to
0.98)
0.87 (0.71 to
1.05)
0.84 (0.71 to
1.00)
0.87 (0.68 to
1.11)
0.86 (0.68 to
1.06)
PTCA v medical
treatment
1.04 (0.75 to
1.30)
0.99 (0.85 to
1.12)
1.00 (0.84 to
1.16)
0.98 (0.83 to
1.15)
0.97 (0.81 to
1.11)
1.03 (0.89 to
1.18)
0.99 (0.85 to
1.14)
1.01 (0.84 to
1.18)
0.96 (0.76 to
1.17)
BMS v medical
treatment
Early generation
DES:
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Table 3 (continued)
Conventional
meta-analysis*
Network meta-analysis
Outcomes by
interventions All trials
Trials with
≥24 months
of follow-up
Trials with
≤10% lost to
follow-up
Excluding all
comer and
post-MI trials
Excluding
CABG trials
Intention to
treat
analysis
Adjudication
blinded
Allocation
concealed
—1.06 (0.87 to
1.27)
1.08 (0.87 to
1.35)
1.05 (0.86 to
1.27)
1.11 (0.88 to
1.36)
1.02 (0.82 to
1.22)
1.15 (0.89 to
1.42)
1.01 (0.79 to
1.25)
1.01 (0.77 to
1.26)
PES v medical
treatment
—0.96 (0.79 to
1.13)
0.97 (0.78 to
1.19)
0.97 (0.79 to
1.17)
1.04 (0.83 to
1.26)
0.91 (0.74 to
1.10)
1.02 (0.81 to
1.24)
0.92 (0.73 to
1.12)
0.88 (0.67 to
1.10)
SES v medical
treatment
—0.85 (0.67 to
1.05)
0.87 (0.66 to
1.10)
0.86 (0.68 to
1.07)
0.79 (0.58 to
1.04)
0.83 (0.65 to
1.03)
0·97 (0.73 to
1.23)
0.82 (0.62 to
1.04)
0.83 (0.62 to
1.07)
E-ZES v medical
treatment
New generation
DES:
—0.81 (0.59 to
1.10)
0.79 (0.49 to
1.26)
0.81 (0.59 to
1.09)
NA0.78 (0.57 to
1.05)
NA0.79 (0.56 to
1.10)
0.77 (0.53 to
1.08)
R-ZES v medical
treatment
0.87 (0.43 to
1.74)
0.78 (0.63 to
0.96)
0.80 (0.62 to
1.03)
0.78 (0.62 to
0.96)
0.78 (0.58 to
1.03)
0.76 (0.60 to
0.93)
0.90 (0.49 to
1.63)
0.78 (0.60 to
0.97)
0.75 (0.56 to
0.96)
EES v medical
treatment
94 trials with
234 693 PY
49 trials with
205 311 PY
75 trials with
195 561 PY
79 trials with
155 514 PY
75 trials with
176 020 PY
65 trials with
189 933 PY
53 trials with
185 573 PY
66 trials with
183 001 PY
Subsequent
revascularisation:
0.17 (0.09 to
0.28)
0.16 (0.13 to
0.20)
0.18 (0.15 to
0.21)
0.15 (0.12 to
0.19)
0.16 (0.13 to
0.20)
—0.17 (0.14 to
0.21)
0.17 (0.14 to
0.20)
0.16 (0.12 to
0.21)
CABG v medical
treatment
0.87 (0.62 to
1.26)
0.97 (0.82 to
1.16)
0.93 (0.77 to
1.11)
0.94 (0.76 to
1.16)
0.97 (0.80 to
1.16)
0.92 (0.78 to
1.08)
0.93 (0.77 to
1.12)
0.87 (0.71 to
1.05)
0.87 (0.68 to
1.11)
PTCA v medical
treatment
0.76 (0.49 to
1.23)
0.69 (0.59 to
0.82)
0.71 (0.61 to
0.82)
0.66 (0.53 to
0.82)
0.69 (0.58 to
0.82)
0.65 (0.56 to
0.76)
0.74 (0.62 to
0.88)
0.70 (0.61 to
0.81)
0.63 (0.50 to
0.81)
BMS v medical
treatment
Early generation
DES:
—0.44 (0.35 to
0.55)
0.41 (0.33 to
0.52)
0.41 (0.32 to
0.54)
0.44 (0.34 to
0.57)
0.41 (0.33 to
0.50)
0.43 (0.33 to
0.57)
0.47 (0.39 to
0.58)
0.40 (0.30 to
0.54)
PES v medical
treatment
—0.29 (0.24 to
0.36)
0.33 (0.27 to
0.40)
0.27 (0.21 to
0.35)
0.28 (0.22 to
0.36)
0.26 (0.21 to
0.32)
0.29 (0.23 to
0.38)
0.32 (0.27 to
0.39)
0.26 (0.20 to
0.35)
SES v medical
treatment
—0.38 (0.29 to
0.51)
0.39 (0.30 to
0.51)
0.36 (0.26 to
0.50)
0.38 (0.27 to
0.54)
0.34 (0.27 to
0.44)
0.39 (0.28 to
0.54)
0.40 (0.32 to
0.51)
0.34 (0.24 to
0.49)
E-ZES v medical
treatment
New generation
DES:
—0.26 (0.17 to
0.40)
0.31 (0.19 to
0.49)
0.25 (0.15 to
0.39)
NA0.25 (0.16 to
0.36)
NA0.29 (0.20 to
0.42)
0.24 (0.15 to
0.38)
R-ZES v medical
treatment
0.16 (0.09 to
0.28)
0.27 (0.21 to
0.35)
0.28 (0.22 to
0.36)
0.26 (0.19 to
0.34)
0.30 (0.22 to
0.42)
0.25 (0.20 to
0.31)
0.27 (0.07 to
0.95)
0.29 (0.23 to
0.36)
0.24 (0.18 to
0.33)
EES v medical
treatment
CABG=coronary artery bypass grafting; MI=myocardial infarction; PY=patient years; PTCA=percutaneous transluminal coronary angioplasty; BMS=bare metal
stent; DES=drug eluting stent; PES=paclitaxel eluting stent; SES=sirolimus eluting stent; R-ZES=zotarolimus eluting (Resolute) stent; E-ZES=zotarolimus eluting
(Endeavor) stent; EES=everolimus eluting stent.
*Conventional random effects meta-analysis of direct randomised comparisons within trials.
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Figures
Fig 1Network of comparisons included in analyses. Circle size is proportional to number of randomised patients and reflects
sample size, whereas line width is proportional to number of comparisons. CABG=coronary artery bypass grafting;
PTCA=percutaneous transluminal coronary angioplasty; BMS=baremetal stents; PES=paclitaxel eluting stent; SES=sirolimus
eluting stent; E-ZES=zotarolimus eluting (Endeavor) stent; R-ZES=zotarolimus eluting (Resolute) stent; EES=everolimus
eluting stent
Fig 2 Accumulation of randomised evidence according to comparison over time. Cumulative number of patients randomly
assigned to different types of intervention according to start of patient enrolment in each trial is presented. CABG=coronary
artery bypass grafting; PTCA=percutaneous transluminal coronary angioplasty; BMS=bare metal stent; DES=drug eluting
stent
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Fig 3 Estimated rate ratios (95% credibility intervals) for mortality, myocardial infarction, the composite of death or myocardial
infarction, and subsequent revascularisation from network meta-analyses for different revascularisation modalities compared
with medical treatment—overall analyses. Square size is proportional to statistical precision of estimates. CABG=coronary
artery bypass grafting; PTCA=percutaneous transluminal coronary angioplasty; BMS=bare metal stents; PES=paclitaxel
eluting stent; SES=sirolimus eluting stent; E-ZES=zotarolimus eluting (Endeavor) stent; R-ZES=zotarolimus eluting (Resolute)
stent; EES=everolimus eluting stent
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Fig 4 Estimated rate ratios (95% credibility intervals) for mortality, myocardial infarction, the composite of death or myocardial
infarction, and subsequent revascularisation from network meta-analyses for different revascularisation modalities compared
with medical treatment—secondary analyses of contemporary trials initiated in 1999 or later. Square size is proportional to
statistical precision of estimates. CABG=coronary artery bypass grafting; PTCA=percutaneous transluminal coronary
angioplasty; BMS=bare metal stents; PES=paclitaxel eluting stent; SES=sirolimus eluting stent; E-ZES=zotarolimus eluting
(Endeavor) stent; R-ZES=zotarolimus eluting (Resolute) stent; EES=everolimus eluting stent
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